Alzamend Neuro Statistics
Share Statistics
Alzamend Neuro has 4.48M shares outstanding. The number of shares has increased by -45.37% in one year.
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -50.69% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.19M |
| Failed to Deliver (FTD) Shares | 451 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 222.51K, so 4.97% of the outstanding shares have been sold short.
| Short Interest | 222.51K |
| Short % of Shares Out | 4.97% |
| Short % of Float | 5.21% |
| Short Ratio (days to cover) | 0.75 |
Valuation Ratios
The PE ratio is -0.48 and the forward PE ratio is -0.34.
| PE Ratio | -0.48 |
| Forward PE | -0.34 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -1.85 |
| P/FCF Ratio | -0.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Alzamend Neuro Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of -0.12.
| Current Ratio | 0.14 |
| Quick Ratio | 0.14 |
| Debt / Equity | -0.12 |
| Total Debt / Capitalization | -13.11 |
| Cash Flow / Debt | -27.5 |
| Interest Coverage | -983.83 |
Financial Efficiency
Return on equity (ROE) is 3.83% and return on capital (ROIC) is 433.3%.
| Return on Equity (ROE) | 3.83% |
| Return on Assets (ROA) | -15.75% |
| Return on Capital (ROIC) | 433.3% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.49M |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -88.1% in the last 52 weeks. The beta is -0.04, so Alzamend Neuro 's price volatility has been lower than the market average.
| Beta | -0.04 |
| 52-Week Price Change | -88.1% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 4.37 |
| Relative Strength Index (RSI) | 35.5 |
| Average Volume (20 Days) | 221.51K |
Income Statement
In the last 12 months, Alzamend Neuro had revenue of $0 and earned -$9.95M in profits. Earnings per share was $-14.72.
| Revenue | 0 |
| Gross Profit | -50.74K |
| Operating Income | -9.94M |
| Net Income | -9.95M |
| EBITDA | -9.89M |
| EBIT | - |
| Earnings Per Share (EPS) | -14.72 |
Balance Sheet
The company has $376.05K in cash and $300.71K in debt, giving a net cash position of $75.33K.
| Cash & Cash Equivalents | 376.05K |
| Total Debt | 300.71K |
| Net Cash | 75.33K |
| Retained Earnings | -54.02M |
| Total Assets | 5.01M |
| Working Capital | 3.51M |
Cash Flow
In the last 12 months, operating cash flow was -$8.27M and capital expenditures -$147.24K, giving a free cash flow of -$8.42M.
| Operating Cash Flow | -8.27M |
| Capital Expenditures | -147.24K |
| Free Cash Flow | -8.42M |
| FCF Per Share | -12.45 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ALZN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1236.97% |
| FCF Yield | -158.05% |
Analyst Forecast
The average price target for ALZN is $35, which is 2841.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 2841.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 16, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 16, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -16.21 |
| Piotroski F-Score | 2 |